ClinicalTrials.gg
CompletedNCT03422575Updated Feb 5, 2018

Bioequivalence Study of 120 mg Etoricoxib Film-coated Tablets

An interventional study of Etoricoxib 120Mg Film-coated Tablet and Arcoxia® 120 mg Film-coated tablet (Frosst Iberica S.A., Spain for Merck Sharp & Dohme (Australia) Pty Limited, Australia, registered by PT. Schering-Plough Indonesia Tbk) in Healthy, sponsored by Dexa Medica Group. Completed at 1 site in Indonesia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-02-05.

Sponsored by Dexa Medica Group · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 2 years 1 month after the study started (first participant enrolled Dec 2015, registered Jan 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The present study was a randomized, open-label, two-period, two-sequence, cross-over study, conducted to find out whether the etoricoxib 120 mg film-coated tablet produced by PT Dexa Medica (test drug) was bioequivalent to the reference drug (Arcoxia® Film-Coated Tablet 120 mg, PT. Schering-Plough Indonesia Tbk), under fasting condition with a fourteen days wash-out period, involving 26 healthy adult male and female subjects.

Read the detailed description

This was a randomized, open-label, two-period, two-sequence, cross-over study under fasting condition with a fourteen days wash-out period, involving 26 healthy adult male and female subjects. The participating subjects had an overnight fast and in the next morning were given orally either one film-coated tablet of the test drug or one film-coated tablet of the reference drug with 200 mL of water. Blood samples were drawn immediately before taking the drug (baseline), and at 15, 30, and 45 minutes and 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, and 72 hours after drug administration, analysed for plasma concentrations of etoricoxib and used to evaluate the pharmacokinetics parameters of the single dose administration. After a fourteen-day washout period, the procedure was repeated using the alternate drug. The plasma concentrations of etoricoxib were determined by using a high pressure liquid chromatography with ultraviolet detection (HPLC-UV) method.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Dexa Medica Group is the lead sponsor of 44 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female subjects Healthy was defined as the absence of significant disease or abnormal laboratory values on laboratory evaluation, medical history or physical examination during screening.
  2. Aged 18 - 55 years inclusive.
  3. Preferably non-smokers or smoke less than 10 cigarettes per day.
  4. Able to participate and would provide written to participate.
  5. within 18 to 25 kg/m2.
  6. Vital signs (after 10 minutes rest) were within the following ranges:

SBP 100 - 120 mmHg ; DBP 60 - 80 mmHg; HR 60 - 90 bpm.

Exclusion criteria

Exclusion Criteria:

  1. Personal/family history of allergy or or to etoricoxib or allied drugs.
  2. Pregnant or lactating women.
  3. Any major illness in the past 90 days or ongoing chronic illness
  4. Presence of any clinically significant abnormal laboratory values during screening.
  5. Positive surface antigen (HBsAg), anti-, or anti-.
  6. Clinically significant hematology abnormalities.
  7. Clinically significant (ECG) abnormalities.
  8. Any surgical or medical condition (present or history) which might significantly alter the absorption, distribution, metabolism or excretion of the study drug, e.g. gastrointestinal disease including gastric or duodenal ulcers or history of gastric surgery.
  9. Past history of anaphylaxis or angioedema.
  10. History of drug or alcohol abuse within 12 months prior to screening for this study.
  11. Participation in any clinical trial within the past 90 days calculated from the last visit.
  12. History of any bleeding or coagulative disorders.
  13. History of difficulty with donating blood or difficulty in accessibility of veins in left or right arm.
  14. A donation or loss of 300 mL (or more) of blood within 3 months before this study's first dosing day.
  15. Intake of any prescription, non-prescription drug, food supplement or herbal medicine within 14 days of this study's first dosing day.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Test

    Etoricoxib 120Mg film-coated Tablet at single dose was given to subjects in this arm.

    Drug: Etoricoxib 120Mg Film-coated Tablet

  • Active comparator
    Reference

    Arcoxia® 120 mg Film-coated tablet (Frosst Iberica S.A., Spain for Merck Sharp \& Dohme (Australia) Pty Limited, Australia, registered by PT. Schering-Plough Indonesia Tbk) was given to subjects in this arm.

    Drug: Arcoxia® 120 mg Film-coated tablet (Frosst Iberica S.A., Spain for Merck Sharp & Dohme (Australia) Pty Limited, Australia, registered by PT. Schering-Plough Indonesia Tbk)

Interventions

06

What researchers measure

Primary outcomes

  1. AUC(0-t)

    The area under plasma concentration-time curve from time zero to last observed concentration truncated at 72-hour (AUC0-72h)

    Time frame: 72 hours

  2. Cmax

    Maximum plasma concentration

    Time frame: 72 hours

Secondary outcomes

  1. Tmax

    Time to maximum plasma concentration

    Time frame: 72 hours

  2. T1/2

    The terminal half-life

    Time frame: 72 hours

07

Study locations

1 site
  • PT Equilab International
    Jakarta, 12430, Indonesia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2015 to primary completion in Dec 2015, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2018
First posted
Feb 5, 2018
StartActual
Dec 2015
Primary completionActual
Dec 2015
CompletionActual
Mar 2016
Last update
Feb 5, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03422575
Lead sponsor
Dexa Medica Group
Collaborators
PT Equilab International
Responsible party
Sponsor
First posted
Feb 5, 2018
Start date
Dec 2015
Primary completion
Dec 2015
Completion
Mar 2016
Last update
Feb 5, 2018

Study contacts

Effi Setiawati, MSc
study director · Equilab International

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etoricoxib

Start the discussion